Overview
BIIB market data
Price History
BIIB price chart · 1M
- O
- 228.06
- H
- 228.39
- L
- 223.84
- C
- 227.61
- Vol
- 55,312.00
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $228.06
- Previous Close
- $226.44
- Day High
- $228.39
- Day Low
- $223.84
- 52 Week High
- $229.19
- 52 Week Low
- $185.10
- 7 Day Return
- +5.51%
- 30 Day Return
- +2.97%
- 90 Day Return
- +5.14%
- 1 Year Return
- +16.05%
- Daily Notional Volume
- $12.6M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 39.87 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $8.79 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.12 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 8.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $135.39 – $229.19 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $33.3B · P/B 1.41 · P/S 3.32.
Company News
10 captured
Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive LandscapeGlobenewswire Inc ·
Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta TherapeuticsGlobenewswire Inc ·
Hummingbird Bioscience Appoints Dr. James Garner as PresidentGlobenewswire Inc ·
Lilly Builds Neuroscience into a New Long-Term Growth DriverZacks Investment Research ·